FDA — authorised 8 May 2003
- Application: ANDA076204
- Marketing authorisation holder: TEVA
- Indication: Labeling
- Status: approved
🇺🇸 MOEXIPRIL in United States
FDA authorised MOEXIPRIL on 8 May 2003
Marketing authorisations
FDA — authorised 30 November 2006
- Application: ANDA077536
- Marketing authorisation holder: CHARTWELL RX
- Status: approved
FDA — authorised 30 March 2010
- Application: ANDA090416
- Marketing authorisation holder: GLENMARK PHARMS LTD
- Status: approved
MOEXIPRIL in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is MOEXIPRIL approved in United States?
Yes. FDA authorised it on 8 May 2003; FDA authorised it on 30 November 2006; FDA authorised it on 30 March 2010.
Who is the marketing authorisation holder for MOEXIPRIL in United States?
TEVA holds the US marketing authorisation.